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Antibody-dependent cell-mediated cytotoxicity (ADCC) specific for human immunodeficiency virus (HIV)
has been described for HIV-infected individuals. To determine the antigenic specificity of this immune response
and to define its relationship to the disease state, an ADCC assay was developed using Epstein-Barr
virus-transformed lymphoblastoid cell line targets infected with vaccinia virus vectors expressing HIV proteins.
The vaccinia virus vectors induced appropriate HIV proteins (envelope glycoproteins gpl60, gpl20, and gp4l
or gag proteins p55, p40, p24, and p17) in infected lymphoblastoid cell lines as demonstrated by radioimmu-
noprecipitation and syncytia formation with c8166 cells. Killer cell-mediated, HIV-specific ADCC was found in
sera from HIV-seropositive but not HIV-seronegative hemophiliacs. This HIV-specific response was directed
against envelope glycoprotein but was completely absent against target cells expressing the HIV gag proteins.
The ADCC directed against gpl60 was present at serum dilutions up to 1/316,000. There was no correlation
between serum ADCC titer and the stage of HIV-related illness as determined by T-helper-cell numbers. These
experiments clearly implicated gp160 as the target antigen of HIV-specific ADCC activity following natural
infection. Vaccines which stimulate antibodies directed against gpl60, which are capable of mediating ADCC
against infected cells, could be important for protection against infection by cell-associated virus.
The acquired immunodeficiency syndrome is the ultimate
result of infection with the human retrovirus human immu-
nodeficiency virus (HIV) (15). Natural infection with this
virus usually occurs after contact with infected blood or
genital secretions (15), both of which are lymphocyte-con-
taining fluids. Recent evidence suggests that semen contains
both monocytes/macrophages and CD4+ lymphocytes which
could be infected with HIV (29), indicating the possible
importance of cell-associated virus in HIV transmission.
One hypothesized method by which the body can protect
itself against cell-associated virus invasion is by the action of
antibodies which mediate antibody-dependent cell-mediated
cytotoxicity (ADCC), in which cells expressing appropriate
viral antigens are lysed, in a non-major histocompatibility
complex-restricted manner, in the presence of antibodies
and killer cells (8). Considering the probable contribution of
cell-associated HIV to disease transmission, potential vac-
cines should be able to stimulate antibodies capable of
mediating ADCC against infected cells, in order to offer
maximum host protection.
It has recently been shown that high titers of HIV-specific
ADCC antibodies can be found in sera from HIV-antibody-
positive individuals (2, 10, 16, 21), but whether this antibody
is predominantly directed against p55/p24/pl7 (gag) or
gp120/gp41 (envelope) determinants remains controversial.
Vaccinia virus (VV) vectors have been used successfully to
express foreign viral proteins in target cells and have been
instrumental in delineating target antigens of virus-specific
cytotoxic T lymphocytes in HIV (26) and other virus (12)
infections. A recent report indicates that VV vectors can
also be used successfully in HIV-specific ADCC assays (23).
In the present study we used a series of VV vectors to
* Corresponding author.
express proteins from the envelope and gag genes of HIV to
delineate the target antigens of HIV-specific ADCC antibod-
ies in the sera of HIV-infected hemophiliacs. In addition, we
attempted to correlate these ADCC responses with other
known prognostic indicators of HIV disease progression.
MATERIALS AND METHODS
Sera. Samples were obtained from the extensive serum
bank which is maintained for sera of approximately 150
hemophilia patients as part of an ongoing study of immuno-
regulatory defects in hemophilia (25). All samples were
maintained at -80°C and were heat inactivated for 30 min at
56°C prior to assay. HIV serology was determined by
Western blot (immunoblot).
Lymphocyte separation. Peripheral blood mononuclear
cells (PBMCs) from healthy HIV-seronegative laboratory
controls (for ADCC assay) or hemophilia patients (for sur-
face marker analysis) were isolated from freshly drawn
heparinized venous blood by centrifugation on Ficoll-Paque
(Pharmacia Fine Chemicals, Piscataway, N.J.) density gra-
dients (25). PBMC preparations contained 70 to 80% lym-
phocytes, 10 to 20% monocytes, and <20% polymorphonu-
clear leukocytes as determined by cell morphology.
Lymphocyte surface marker studies. The relative percent-
age of the CD4 lymphocyte population was determined by
direct immunofluorescence with phycoerythrin-conjugated
mouse monoclonal antibody Leu3a (Becton Dickinson and
Co., Mountain View, Calif.). Samples were analyzed with a
FACS 440 fluorescence-activated cell sorter (Becton Dick-
inson). Absolute numbers of CD4 lymphocytes per microli-
ter of blood were determined by multiplying the relative
percentage by the absolute number of PBMCs as determined
from complete blood counts.
VV vectors. Molecular clones containing sequences encod-
584
 at UNIV O
F M
ASS M
ED SCH on August 5, 2008 
jvi.asm.org
D
ow
nloaded from
 
ADCC TO HUMAN IMMUNODEFICIENCY VIRUS 585
ing envelope, gag, or pol genes from HIV strain BH10
(vAbT 140, 141, or 228) or HXB2 (vAbT 200) (20) were
inserted into VV strain NYCBH (ATCC VR-325) by meth-
ods previously described (11, 14). Briefly, plasmid vectors
that direct the insertion and expression of both the HIV gene
of interest and the Escherichia coli lacZ gene into the
thymidine kinase (tk) locus of VV were constructed. These
plasmids, which contain the HIV gene under the control of
the VV 7.5K (vAbT 140, 141, or 200) .or 40K (vAbT 228)
promoter (30), the E. coli lacZ gene under the control of the
VV Hind-F promoter (17), and flanking sequences from the
VV tk gene (17) were introduced into BSC-40 cells (3)
previously infected with VV. Homologous recombination
between plasmid and virus in the tk region resulted in
recombinant viruses which were selected on the basis of
their TK- phenotype (27) and identified as blue plaques, due
to expression of P-galactosidase, in the presence of the
chromogenic substrate halogenated indolyl-4-D-galactoside
(Bluo-Gal; Bethesda Research Laboratories, Gaithersburg,
Md.) (17). Expression of the desired HIV antigen was
confirmed by an in situ enzyme-linked immunosorbent assay
(ELISA) (black-plaque assay) as described below. Recom-
binant vAbT 140 contains the entire HIV envelope-coding
sequence and 96 base pairs (bp) of 5'-proximal and 107 bp of
3 '-proximal untranslated sequences. Recombinant vAbT 141
contains the entire HIV gag coding sequence beginning at
the translation initiation codon and extending approximately
200 bp beyond the gag translation termination codon.
Recombinant vAbT 200 contains the entire HIV gag and pol
genes beginning at the initiation codon of gag and extending
to the NdeI site 26 bp beyond the pol translation termination
codon. Recombinant vAbT 228 contains gag sequences from
the initiation codon of gag through the PvuII site, 38 bp
upstream of the end of p17 coding sequences. A synthetic
linker was added to restore the terminal sequences of p17,
along with a stop codon and a VV transcription termination
sequence. The predicted molecular structures of the recom-
binant viruses were confirmed by restriction endonuclease
analysis and DNA hybridization of viral genomic DNA. VV
strain NYCBH was used as the control virus in all ADCC
studies.
Expression analysis. Expression of the HIV antigens by the
recombinant VV vectors was confirmed in BSC-40 cells by
an in situ ELISA performed directly on viral plaques (24).
Incubation with 4D12.1 (monoclonal anti-p55; Epitope, Bea-
verton, Oreg.), NEA-9303 (monoclonal anti-gp4l; Du Pont
Co., Wilmington, Del.), or p17 Monobody (Cellular Prod-
ucts, Buffalo, N.Y.) was followed by incubation with alka-
line phosphatase-labeled goat anti-mouse immunoglobulin G
(Kirkegaard & Perry Laboratories, Gaithersburg, Md.) and
the precipitating substrates 5-bromo-4-chloro-3-indolyl
phosphate and nitro blue tetrazolium (Kirkegaard & Perry).
Radioimmunoprecipitations were done by infecting 106
target cells at a multiplicity of infection of 10 for 4 h (BSC-40)
or 16 h (RH-LCL) in the presence of 100 ,uCi of
[3H]glucosamine (vAbT 140) or [3H]leucine (vAbT 141, 200,
and 228). Harvesting and precipitation were carried out as
previously described (28) by using mouse monoclonal anti-
bodies against HIV antigens, pooled HIV-positive VV-
negative human sera, or specific rabbit antisera from previ-
ously vaccinated animals.
Cell culture supernatants were tested for HIV gag antigen
in an antigen capture ELISA, using a monoclonal antibody
system (Du Pont).
Surface expression of HIV envelope glycoprotein was
assessed by the ability of VV vector-infected cells to form
syncytia with c8166 cells in a 4-h coincubation (26).
ADCC assay. An Epstein-Barr virus (EBV)-transformed B
lymphoblastoid cell line (RH-LCL), created by coincubation
of a B95.8 (ATCC CRL-1612) cell culture supernatant with
the lymphocytes of an 8-year-old HIV-seronegative individ-
ual, was used as the target cell line in these experiments.
RH-LCL cells were infected with VV vectors (NYCBH
and vAbT 140, 141, 200, and 228) at a multiplicity of
infection of 10 by the methods of McMichael et al. (12).
Sixteen hours later the cells were washed, incubated with
100 ,Ci of Na251CrO4 (New England Nuclear Corp., Boston,
Mass.) at 37°C for 60 min, washed twice with phosphate-
buffered saline, and suspended, after viability determination
by trypan blue exclusion, to an appropriate concentration in
RPMI 1640 with 10% heat-inactivated fetal calf serum (FCS).
Ninety microliters of target cell suspension containing 104
target cells was dispersed into wells of 96-well round-bottom
microdilution plates containing 20 RI of serum appropriately
diluted in RPMI 1640 with 10% FCS. After 20 min at room
temperature, 90 ,ul of effector cell suspension containing 2.5
x 105 freshly isolated PBMCs from a healthy HIV-seroneg-
ative laboratory donor was added to the test wells (effector
cell-to-target cell ratio, 25:1). Control wells with RPMI 1640
with 10% FCS in place of effector cells, serum, or both, were
included in all assays. The test plates were centrifuged at 200
x g for 5 min and incubated for 8 h at 37°C in a humidified,
5% CO2 environment. The plates were then recentrifuged at
200 x g for 5 min, 100 ptl of assay supernatant was collected
from each well, and the radioactivity was counted in a
gamma counter (Packard Instrument Co., Inc., Downers
Grove, Ill.). Maximal incorporation was established by
determining the counts per minute (cpm) in a 45-pAl sample of
the target cell suspension. All tests were performed in
triplicate.
Percent ADCC was calculated as percent cytolysis in the
presence of serum minus percent cytolysis in the absence of
serum, where percent cytolysis was calculated by the fol-
lowing formula: 100 x [(test cpm - spontaneous cpm)/
(maximal cpm - spontaneous cpm)].
Effector cell depletions. Effector PBMCs were depleted of
cells expressing a natural killer (NK) phenotype by using
monoclonal antibody and rabbit complement. Briefly,
freshly isolated PBMCs were incubated with monoclonal
antibody Leullb (Becton Dickinson) for 30 min at 4°C in
RPMI 1640 with 2% FCS. After being washed, the cells were
lysed by incubation with rabbit complement (Cederlane
Laboratories Ltd., Hornby, Ontario, Canada) for 60 min at
37°C. The cytotoxic activity of the depleted cells was as-
sessed immediately after depletions. PBMCs incubated with
complement alone were included in all depletion assays as
background controls, and the adequacy of the depletions
was assessed by inhibition of killing of the NK cell-sensitive
erythroleukemia cell line K-562 (ATCC CCL243) in parallel
assays.
Statistical analysis. The data shown in figures represent
means + standard deviations, and n refers to the number of
serum samples tested from separate individuals. Significance
was determined when appropriate by analysis of variance,
and statistical significance was defined as P < 0.05.
RESULTS
The production and processing of HIV proteins in RH-
LCL cells infected with recombinant VV vectors was as-
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TABLE 1. HIV protein expression in RH-LCL cells infected
with recombinant VV vectorsa
Supernatant Syncytia
Vector RIP gag-antigen c8t66
ELISA cells
None (uninfected - - -
RH-LCL cells)
NYCBH
vAbT 140 gp41, gpl2O, gp160 - +
vAbT 141 p55 + -
vAbT 200 p24, p4O, p55 + -
vAbT 228 p17 - -
a Expression of HIV proteins in RH-LCL cells 16 h after infection with
recombinant VV vectors, determined by radioimmunoprecipitation (RIP)
using polyclonal human HIV-seropositive, VV-seronegative serum; HIV
gag-antigen ELISA, using a monoclonal antibody assay system (Du Pont);
and ability of infected cells to form syncytia with c8166 cells.
sessed by radioimmunoprecipitation. The envelope gene
product (gpl60) was found to be produced and processed to
surface protein gp120 and transmembrane protein (9) gp4l in
vAbT 140-infected cells. The gag recombinant vectors pro-
duced unprocessed p55 protein (vAbT 141), processed gag
products p55, p4O, and capsid protein p24 (vAbT 200), or
matrix protein p17 (vAbT 228) (Table 1). Surface expression
of envelope glycoprotein was demonstrated in vAbT 140-
infected RH-LCL cells by their ability to form syncytia with
c8166 cells during a 4-h cocultivation, and immunologically
active extracellular gag protein was demonstrated in vAbT
141- and vAbT 200-infected RH-LCL cells by ELISA of
culture supernatant (Table 1). This production of extracellu-
lar HIV p55 occurred without loss of cell viability over a 24-h
period and therefore did not reflect release of p55 related to
cell death. The presence of gag proteins on the surface of
vAbT 141-, 200-, or 228-infected RH-LCL cells could not,
0
0
C]
a)CL)
(I)0L
Serum A Serum B
however, be demonstrated by indirect immunofluorescence.
This was true despite the use of several HIV-specific mouse
monoclonal antibodies and several different second anti-
body-fluorescein isothiocyanate conjugates.
Having demonstrated appropriate HIV protein production
in VV vector-infected RH-LCL targets, we assayed multiple
serum samples from pediatric and adult hemophilia patients
for their ability to mediate ADCC against NYCBH-infected
and vAbT 140-infected RH-LCL targets. In all HIV-seropos-
itive sera tested, ADCC reacting against targets expressing
HIV surface protein and transmembrane protein was present
at greater serum dilutions than ADCC reacting against
NYCBH-infected targets, allowing for a clear delineation of
these two activities. Indeed, in more than 80% of these sera,
the difference was present at a serum dilution of 1/1,000. No
ADCC against gpl60 above that observed against VV could
be demonstrated in HIV-seronegative sera. Representative
data for three sera are presented in Fig. 1 and demonstrate
HIV gpl60-specific ADCC at a serum dilution of 1/1,000 or
greater, whereas VV- or EBV-specific ADCC was absent at
similar serum dilutions. In all further experiments, sera with
greater than 20% ADCC against NYCBH-infected targets at
a serum dilution of 1/1,000 were discarded (<15% of sera
tested).
NK cells bearing a CD16 phenotype are known to mediate
in vitro ADCC responses (8). The HIV envelope glycopro-
tein-specific ADCC demonstrated by the results in Fig. 1 was
shown to be K-cell mediated, as evidenced by inhibition of
killing after Leullb-directed complement-mediated deple-
tion of effector cells (Table 2).
Having determined that gpl60-specific ADCC was detect-
able with VV vector-infected targets and that the optimum
serum dilution was approximately 1/1,000, we assayed sera
from 19 hemophilia patients (6 HIV seronegative, 7 HIV
seropositive with normal numbers of T helper cells, and 6
HIV seropositive with decreased numbers of T helper cells)
Serum C
-60
50
*40
-30
- 20
- 10
0
io1I lo2 lo-, o-'4 lo-
Serum dilution
FIG. 1. Percent ADCC for three representative sera assayed at various dilutions against RH-LCL targets infected with control VV
NYCBH or with vAbT 140, which expresses HIV envelope gp160. The ability to differentiate VV- from HIV-specific ADCC at a serum
dilution of 1/1,000 (10-3) is evident.
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TABLE 2. NK cell dependence of measured ADCC responsesa
% ADCC against RH- % Cytolysis
LCL cells infected of NK-cellEffectors with: control
NYCBH vAbT 140 K562
PBMCs 0 46 80
PBMCs + complement 2 36 70
PBMCs + anti-Leullb + 0 11 (69) 17 (76)
complement
a NK cells were depleted from effector PBMCs by using anti-Leullb and
rabbit complement and then used in an ADCC assay with a known HIV-
seropositive serum diluted 1/1,000. The numbers in parentheses indicate
percent decreases in ADCC compared with that in the complement control.
Cytolysis of the NK-sensitive cell line K562 was measured in the absence of
added serum and was included as a measure of NK cell depletion.
for their ability to mediate HIV envelope- or gag-specific
ADCC at a serum dilution of 1/1,000. Of the 13 HIV-
seropositive sera tested, 12 had antibodies to p55, 10 had
antibodies to p24, 5 had antibodies to p17, and all 13 had
antibodies to gp4l and gpl20 by Western blot. HIV enve-
lope-specific ADCC activity could be demonstrated at a
serum dilution of 1/1,000 in all 13 HIV-seropositive sera
tested. None of these sera, however, were capable of
mediating HIV gag-specific ADCC against targets express-
ing processed or unprocessed gag antigens at the same
dilution. The six HIV-seronegative sera failed to mediate
ADCC against targets expressing envelope or gag antigens.
Cumulative data for these 19 sera are shown in Fig. 2 and
clearly demonstrate that the HIV-seropositive sera con-
tained a statistically significant (P < 0.01) ADCC activity
against envelope-expressing targets compared with that
against VV- or gag-expressing targets. The level of HIV
envelope-specific ADCC noted in these HIV-seropositive
sera did not differ significantly between individuals with
50
VACCINIA VECTOR SERUM DILUTION = 1/1000
40W*NCBH40-
9 140
o30- 141
C) 0 200
0 228
I-. 20-
z
W10
0 TT T
-10
SERONEGATIVE SEROPOSITrVE SEROPOSrVE
CD4 >400 CD4 < 200
n=6 n=7 n=6
FIG. 2. Cumulative ADCC results for 19 HIV-seropositive and
-seronegative sera assayed at a dilution of 1/1,000. Target cell lines
were RH-LCL infected with vectors NYCBH (control), vAbT 140
(gp4l, gpl20, and gpl60), vAbT 141 (p55), vAbT 200 (p24, p40, and
p55), or vAbT 228 (p17). Error bars represent 1 standard deviation
of the mean. RH-LCL cells infected with vector vAbT 140 were
lysed in the presence of HIV-seropositive sera from individuals with
low or mean-normal numbers of CD4 lymphocytes to a significantly
(P < 0.01) greater degree than were other vector-infected RH-LCL
cells or RH-LCL cells in the presence of HIV-seronegative sera.
40 -
30 -
20-
ZU 10
CC
X O-
-U
-10-
NWCBH 140 141 200 228
VACCINIA VECTOR
FIG. 3. Cumulative ADCC results for eight HIV-seroposiuive
sera assayed over a range of dilutions against RH-LCL cells infected
with NYCBH (control), vAbT 140 (gp4l, gpl20, and gpl60), vAbT
141 (p55), vAbT 200 (p24, p4O, and p55), or vAbT 228 (p17). Error
bars represent 1 standard deviation of the mean. While ADCC
against vAbT 140-infected RH-LCL cells is apparent to a serum
dilution of 1/10,000 or greater, no ADCC is apparent against
gag-expressing targets at any serum dilution.
near-normal (>400/,ul) numbers of T helper cells and those
with severely decreased (<200/,ul) numbers ofT helper cells.
To determine whether the absence of HIV gag-directed
ADCC in HIV-seropositive sera was a result of assaying
nonoptimal serum dilutions, eight HIV-seropositive sera
were assayed over a range of serum dilutions. All eight sera
tested, regardless of maximum cytolysis, showed optimum
envelope-specific ADCC at a serum dilution of 1/1,000. No
HIV gag-specific ADCC was demonstrable in any of the
eight sera tested over a range of serum dilutions from 1/10
through 1/100,000 (Fig. 3). Subsequent experiments per-
formed at higher effector cell-to-target cell ratios (up to 100
to 1) and longer incubation times (up to 12 h) also failed to
demonstrate gag-specific ADCC in any HIV-seropositive
serum tested (data not shown).
The HIV envelope-specific ADCC titers of four sera from
HIV-seropositive hemophiliacs with near-normal numbers
of T helper cells and four sera from HIV-seropositive
hemophiliacs with very low numbers of T helper cells were
determined at half-log dilutions to establish whether ADCC
titer varied between these two groups of patients. HIV
ADCC titer was defined as the greatest serum dilution which
was capable of mediating ADCC against vAbT 140-infected
targets greater than two standard deviations above the mean
ADCC against NYCBH-infected targets for all sera assayed
at that dilution on a given day. By using this system, it was
found that even patients with severe T-helper-cell depletions
maintained high-titer serum HIV-specific ADCC activity and
no difference in titer could be demonstrated between the two
groups (Table 3).
DISCUSSION
ADCC has been shown to be of prognostic importance in
certain viral systems, particularly in chronic or transforming
virus infections. Antibodies to EBV antigens which mediate
ADCC have been shown to be of prognostic importance in
Burkitt's lymphoma and nasopharyngeal carcinoma (18, 19).
SERUM DLUTKON
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* 1/1000
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TAB3LE 3. Serum titer of HIV envelope-specific ADCC
Patient T helper cells/ ADCC
,u1 of blood titera
A 9 1/10,000
B 33 1/100,000
C 72 1/31,600
D 138 1/100,000
E 677 1/10,000
F 705 1/100,000
G 792 1/100,000
H 1,163 1/316,000
a Serum envelope-specific ADCC titers in the sera of four HIV-seropositive
hemophiliacs with near-normal numbers of T helper cells (patients E through
H) and four HIV-seropositive hemophiliacs with very low numbers of T
helper cells (patients A through D). The difference in geometric mean titers
(1/75,000 and 1/42,200, respectively) between the two groups is not statisti-
cally significant.
In addition, human T-cell lymphotropic virus type I (HTLV-
I)-specific ADCC antibodies have been demonstrated in
HTLV-I-infected individuals and have been correlated with
the presence or absence of adult T-cell leukemia (13).
HIV-specific ADCC activity in the sera of infected indi-
viduals has been described (2, 10, 16, 21), and the present
study was undertaken to determine the antigenic specificity
of these ADCC antibodies. Recombinant VV vectors ex-
pressing foreign viral genes have been valuable tools in
defining immune responses in HIV and other viral infections
(12, 26) and were chosen for use in this study for four
reasons. First, HIV is known to infect B cells and EBV-
transformed B-lymphoblastoid cell lines (B-LCLs), allowing
the assay results to have some relevance to in vivo infection
(6). Second, the use of recombinant VVs expressing HIV
genes allows us to present individual HIV proteins in in-
fected cells. Third, B-LCLs infected with VV vectors ex-
pressing foreign viral proteins have been used with great
success in defining the antigenic specificity of virus-specific
cytotoxic T-lymphocyte responses after HIV (26) and other
viral (12) infections, and as a result these cells are known to
be relatively resistant to NK cell lysis in the absence of
antibody. Fourth, HIV envelope-specific ADCC is known to
be measurable with VV vectors expressing this glycoprotein
(23).
Since the majority of the hemophilia patients tested had
antibodies to EBV or VV or both and these viral antigens
were present in the recombinant VV vector-infected B-LCL
target cells, the possibility existed that serum HIV-specifir
ADCC activity would be obscured by VV- or EBV-specific
responses. In our screening, however, we found that serum
HIV-specific ADCC was always present at higher titers than
ADCC activity against uninfected or VV-infected B-LCL
targets. In more than 85% of the sera tested a clear difference
in ADCC against NYCBH-infected targets compared with
that against vAbT 140-infected targets was demonstrable at a
serum dilution of 1/1,000. The low titer of VV-specific
ADCC noted in this hemophiliac population was not unex-
pected since smallpox vaccination represents a remote viral
infection and as a result ADCC titers to this virus have
declined, whereas HIV represents an ongoing infection with
stimulation of high-titer HIV-specific ADCC antibody re-
sponses. In addition, it is known that EBV-transformed
B-LCLs are latently infected with EBV and do not have
surface expression of membrane antigens responsible for
EBV-specific ADCC (1).
We were able to screen multiple serum samples at a
dilution of 1/1,000 in the ADCC assay and demonstrated
K-cell-dependent, HIV-specific responses in all 13 HIV-
seropositive sera and in none of the 6 HIV-seronegative
sera. Other ADCC assay systems have been unable to detect
HIV-specific responses in all HIV-seropositive sera (2, 10,
21). Our ability to more easily detect these responses prob-
ably relates to the high infection rate and HIV protein
presentation in recombinant VV vector-infected targets
compared with HIV-infected targets.
All of the measured ADCC activity in these assays was
directed against targets expressing HIV envelope glycopro-
teins and not gag antigens. When the titers of the HIV
envelope-specific ADCC were determined for a small popu-
lation of HIV-seropositive hemophiliacs, no correlation be-
tween ADCC titer and absolute numbers of T helper cells
could be identified. Indeed, one patient with acquired immu-
nodeficiency syndrome with only nine T helper cells per
microliter of blood and no p24 serum antibody still had a
serum HIV ADCC titer of 1/10,000. Other investigators have
failed to correlate HIV-specific ADCC activity with disease
markers such as T helper/T suppressor cell ratios (10), but
some studies have shown a decrease in ADCC activity after
the development of acquired immunodeficiency syndrome
(2, 10, 21). The failure to corroborate the latter observation
in our study may simply relate to the low number of serc
tested.
One previous study of HIV-specific ADCC responses was
able to correlate decrease or absence of ADCC activity with
the disappearance of Western blot reactivity with p24 anti-
gen (22), whereas others have not reported similar findings
and indeed have reported a correlation between ADCC
activity and antibody to gpl20 and gp4l (2, 10, 16). In our
study we were unable to detect any serum ADCC activity
against targets expressing gag antigens. This inability to
detect serum gag-specific ADCC occurred despite the fact
that Western blots confirmed the presence of gag-specific
immunoglobulin G in the sera of 12 of the 13 HIV-seropos-
itive individuals tested.
The absence of serum ADCC activity against gag antigens
probably relates to the fact that these proteins are not known
to be present on the cell surface. We were able to detect
intracellular gag antigens in vAbT 141-, 200-, and 228-
infected target cells and extracellular gag antigens in vAbT
141- and 200-infected cells but could not determine their
presence on the cell surface by indirect immunofluorescent
staining. This is probably not unique to the way gag antigens
are produced in VV vectors, as other groups have also failed
to detect surface expression of gag antigens in HIV-infected
cells by using gag-specific monoclonal antibodies (5, 7). In
addition, Evans et al. (7) have recently shown that a human
immunoglobulin G4 monoclonal antibody which reacts with
HIV p55 and p25 is incapable of mediating ADCC against
HIV-infected targets.
One must also consider the possibility that individual
antigens as expressed by vector-infected cells may be pre-
sented differently than they are in naturally infected cells.
The envelope glycoprotein of HIV, as expressed in recom-
binant VV vectors, is known to be processed and glycosy-
lated normally (4), and the end products become situated in
the outer cell membrane in a manner which allows for
spontaneous syncytia formation in the presence of CD4-
bearing cells (26). As such, this viral product appears to be
presented in much the same manner as it would be in
HIV-infected cells. Less is known, however, about the
natural presentation of gag antigens in HIV-infected cells. It
has been suggested that the p17 product of the gag gene may
J. VIROL.
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actually protrude through the surface of the intact virion
(22), and therefore it could be postulated that p17 may
protrude through the surface of the cell membrane during the
process of viral budding and as a result be a target antigen of
ADCC. Our inability to detect ADCC activity against cells
infected with a vector expressing p17 does not support this
theory, although it is possible that envelope glycoproteins
are required for the correct orientation and anchoring of the
p17 molecule in the budding virion. Studies in our laboratory
and those of others have been able to show that recombinant
VV vector-infected B-LCL targets present gag antigens on
their surfaces which are recognized by cytotoxic T lympho-
cytes from HIV-infected patients (26; R. A. Koup, J. L.
Sullivan, P. H. Levine, D. Brettler, S. McKenzie, and D.
Panicali, Clin. Res. 36:575A, 1988), but these antigens prob-
ably represent small amphipathic peptides presented in the
context of major histocompatibility complex molecules
which are recognized by T cells and not antibodies.
In conclusion, the present study demonstrates that VV
vectors expressing foreign viral proteins, which have been
used with great success in elucidating cellular immune
responses to virus infection, can also be used to delineate
combined humoral and cellular immune responses to virus
infection in the form of ADCC. This study clearly identified
the envelope glycoprotein complex gpl20/gp41 as a major
target antigen of HIV-specific ADCC antibodies and estab-
lished that these antibodies were present at high titer and
remained at high titer even in advanced stages of disease.
Although we were unable to demonstrate gag antigens as
targets for ADCC antibodies in our system, the differences
between antigen presentation in vector-infected and HIV-
infected cells does not allow us to rule these out as possible
target antigens of HIV-specific ADCC in some HIV-infected
cells.
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